The apparent clinical implications of these observations are that 1) in post-menopausal women with ER-positive breast cancer, T4 may serve an estrogen-like function on tumor cell proliferation and 2) in pre-menopausal patients with breast cancer, T4 may be a stimulatory factor, regardless of estrogen receptor status of the disease. Here, ESR1 is linked to breast cancer.